H&H國際控股(01112.HK)2021年收入115.48億元 同比增長3.2%
H&H國際控股(01112.HK)公吿,截至2021年12月31日止年度業績,公司實現收入115.48億元,同比增長3.2%;經調整可比純利9.53億元,同比減少12.4%;母公司普通股權益持有人應占每股盈利0.79元。董事會欣然建議就截至2021年12月31日止年度派付末期股息每股普通股0.17港元。
集團的收入增長主要得益於成人營養及護理用品及寵物營養及護理用品業務的持續穩健增長以及Zesty Paws的收入自2021年10月4日收購事項完成起綜合入賬。按同類比較附註基準,集團的收入下降3.8%,主要由於中國內地的嬰幼兒營養及護理用品業務受出生率下降及競爭日益激烈影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.